These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27027783)

  • 1. New insights into the evaluation of randomized controlled trials for rare diseases over a long-term research horizon: a simulation study.
    Bayar MA; Le Teuff G; Michiels S; Sargent DJ; Le Deley MC
    Stat Med; 2016 Aug; 35(19):3245-58. PubMed ID: 27027783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Group sequential adaptive designs in series of time-to-event randomised trials in rare diseases: A simulation study.
    Bayar MA; Le Teuff G; Koenig F; Le Deley MC; Michiels S
    Stat Methods Med Res; 2020 Jun; 29(6):1483-1498. PubMed ID: 31354106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taking the long view: how to design a series of Phase III trials to maximize cumulative therapeutic benefit.
    Deley MC; Ballman KV; Marandet J; Sargent D
    Clin Trials; 2012 Jun; 9(3):283-92. PubMed ID: 22569743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
    Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
    J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A strategic view of randomized trial design in low-incidence paediatric cancer.
    Sposto R; Stram DO
    Stat Med; 1999 May; 18(10):1183-97. PubMed ID: 10363339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative evaluation of single-arm versus randomized phase II cancer clinical trials.
    Pond GR; Abbasi S
    Clin Trials; 2011 Jun; 8(3):260-9. PubMed ID: 21511687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinded sample size recalculation in clinical trials incorporating historical data.
    Hees K; Kieser M
    Contemp Clin Trials; 2017 Dec; 63():2-7. PubMed ID: 28735110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of information analysis optimizing future trial design from a pilot study on catheter securement devices.
    Tuffaha HW; Reynolds H; Gordon LG; Rickard CM; Scuffham PA
    Clin Trials; 2014 Dec; 11(6):648-56. PubMed ID: 25084784
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A small n sequential multiple assignment randomized trial design for use in rare disease research.
    Tamura RN; Krischer JP; Pagnoux C; Micheletti R; Grayson PC; Chen YF; Merkel PA
    Contemp Clin Trials; 2016 Jan; 46():48-51. PubMed ID: 26586608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer.
    Gan HK; You B; Pond GR; Chen EX
    J Natl Cancer Inst; 2012 Apr; 104(8):590-8. PubMed ID: 22491345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient ways exist to obtain the optimal sample size in clinical trials in rare diseases.
    van der Lee JH; Wesseling J; Tanck MW; Offringa M
    J Clin Epidemiol; 2008 Apr; 61(4):324-30. PubMed ID: 18313556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalized optimal design for two-arm, randomized phase II clinical trials with endpoints from the exponential dispersion family.
    Jiang W; Mahnken JD; He J; Mayo MS
    Pharm Stat; 2016 Nov; 15(6):459-470. PubMed ID: 27511063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increasing trial efficiency by early reallocation of placebo nonresponders in sequential parallel comparison designs: application to antidepressant trials.
    Boessen R; Knol MJ; Groenwold RH; Grobbee DE; Roes KC
    Clin Trials; 2012 Oct; 9(5):578-87. PubMed ID: 23060319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival distributions impact the power of randomized placebo-phase design and parallel groups randomized clinical trials.
    Abrahamyan L; Li CS; Beyene J; Willan AR; Feldman BM
    J Clin Epidemiol; 2011 Mar; 64(3):286-92. PubMed ID: 20926258
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.